Intellia Therapeutics, Inc. $NTLA Shares Sold by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. trimmed its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 11.8% during the third quarter, HoldingsChannel reports. The firm owned 2,354,856 shares of the company’s stock after selling 316,409 shares during the period. Amova Asset Management Americas Inc.’s holdings in Intellia Therapeutics were worth $40,621,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. AQR Capital Management LLC boosted its stake in Intellia Therapeutics by 154.1% during the first quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock worth $646,000 after buying an additional 55,118 shares during the last quarter. Woodline Partners LP acquired a new position in shares of Intellia Therapeutics during the 1st quarter valued at about $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Intellia Therapeutics by 8.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock valued at $3,709,000 after purchasing an additional 38,521 shares during the period. Atria Investments Inc acquired a new stake in Intellia Therapeutics during the second quarter worth about $96,000. Finally, Vestmark Advisory Solutions Inc. raised its position in shares of Intellia Therapeutics by 104.7% during the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 638,342 shares of the company’s stock valued at $5,988,000 after buying an additional 326,460 shares during the period. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds / allows second in‑human trial to resume, removing a major regulatory overhang and clearing Intellia to restart an important gene‑editing program. Read More. Read More.
• Positive Sentiment: Multiple analyst upgrades and target increases (JonesTrading to Buy, Leerink & HC Wainwright bumping targets, William Blair upgrade to Outperform) have supported sentiment and likely drove buying interest. JonesTrading set a $29 PT; HC Wainwright raised its PT to $30. Read More. Read More.
• Positive Sentiment: Intellia presented longer‑term clinical data for lonvoguran (lonvo‑z) at AAAAI showing multi‑year follow‑up after a one‑time dose — reinforces the durability narrative for a key therapeutic candidate. Read More.
• Positive Sentiment: High‑profile investor interest: Cathie Wood’s Ark (coverage piece) noted buying activity in beaten‑up growth names, including Intellia — a potential source of additional demand from momentum/growth investors. Read More.
• Neutral Sentiment: Other broker moves mixed: RBC, Wells Fargo and others nudged targets modestly higher (to ~$15), while Canaccord cut its target from $54 to $48 — consensus remains wide, reflecting varying views on timelines and commercialization risk. Read More.
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates across several 2026 quarters and lowered full‑year forecasts slightly even while maintaining a Buy and a $30 PT — a reminder analysts expect continued cash burn and negative earnings into 2026. This raises execution risk and could limit multiple expansion. Read More.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NTLA. William Blair raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday. Royal Bank Of Canada lifted their price target on shares of Intellia Therapeutics from $9.00 to $15.00 and gave the company a “sector perform” rating in a research report on Tuesday. Evercore set a $8.00 price target on shares of Intellia Therapeutics and gave the company an “in-line” rating in a research note on Tuesday, November 11th. Chardan Capital reaffirmed a “buy” rating and set a $26.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 27th. Finally, Wall Street Zen downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 18th. Eleven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Intellia Therapeutics presently has an average rating of “Hold” and an average target price of $19.59.

Intellia Therapeutics Stock Performance

NTLA stock opened at $13.82 on Thursday. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.25. The company’s 50 day moving average price is $12.17 and its 200 day moving average price is $13.10. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -3.61 and a beta of 2.10.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.16. The business had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The company’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same period in the previous year, the company earned ($1.27) EPS. Equities analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 34,146 shares of Intellia Therapeutics stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $314,484.66. Following the sale, the chief executive officer directly owned 1,013,339 shares in the company, valued at $9,332,852.19. This trade represents a 3.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the transaction, the executive vice president owned 98,533 shares of the company’s stock, valued at $907,488.93. This represents a 7.95% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 53,051 shares of company stock valued at $488,600. 3.10% of the stock is currently owned by corporate insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.